Prurigo nodularis indicates a skin condition in which hard, itchy nodules or lumps develop on the skin surface. This condition can vary from mild to severe case and it is categorised under the chronic inflammatory rare disease of unknown aetiology. Advancements of diagnostics technology and diagnosis seeking rate are expected to boost prurigo nodularis treatment market growth. Future Market Insights (FMI), the market will exhibit 3% Y-o-Y growth in 2021. With prevalence of the disease forecast to rise, accelerated demand is likely in the near future.
Leading market players are currently focusing on strategic collaborations with various healthcare institutes, universities, governmental agencies, start-up organizations and industry suppliers. This is intended to expand their footprint as well as drive various research and development initiatives.
Besides efforts by market players, initiatives undertaken by regulatory bodies to improve the development and approval process of orphan drug will aid the overall prurigo nodularis treatment market growth. According to FMI, the capsaicin cream segment by drug class is anticipated to gain the momentum significantly contributing towards market growth in the coming years. It is expected to account for over 40% of the market in 2020.
To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-3339
Key Takeaways from Prurigo Nodularis Treatment Market Study
- The demand from the U.S. is expected to rise at a steady pace. It is expected to account for over 91% of the North America market
- France will emerge as a lucrative market, registering above 3% Y-o-Y growth in 2021
- The U.K. and Germany will emerge as other key markets for prurigo nodularis treatment in Europe
- Within East Asia, Japan and China will record rising demand for Prurigo nodularis treatment.
“Increasing research and development activities are expected to boost the growth for prurigo nodularis treatment market. On the other hand, there is high prevalence of unmet needs in the therapeutic domain of rare diseases. This will create impressive growth opportunities for key players contributing towards growth of the market” says the FMI Analyst
Who is Winning?The global market is set to expand steadily over the forecast period, driven by the increasing prevalence of prurigo nodularis, advancements in technology, and adoption of prurigo nodularis treatment drugs which can be used for long term care needs. In addition to this, changing regulatory dynamics and lack of adequate knowledge has constrained the sales of prurigo nodularis treatment drugs.
Product approvals by the U. S. Food and Drug Administration (FDA) for prurigo nodularis treatment drugs are expected to push towards high competition among market players. For Instance, in December 2019, Galderma SA announced the breakthrough therapy designation to its drug Nemolizumab from the U.S. FDA for treatment of prurigo nodularis.
Some of the key market players covered by FMI include Bayer AG, Pfizer Inc., GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Novartis AG, Celgene Corporation, Galderma SA (Nestle Skin Health Company), VYNE Therapeutics Inc., Trevi Therapeutics Inc. consolidating their positions through mergers, acquisitions and new product launches.
Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3339
Want more insights?Future Market Insights (FMI) brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2030. The global prurigo nodularis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on prurigo nodularis treatment market on basis of drug class such as corticosteroids (injectable, topical, oral), emollients, capsaicin cream, antihistamines, anticonvulsants, antidepressants, neurokinin 1 receptor (NK1R), opiate receptor antagonists and others. And based on distribution channels such as hospital pharmacies, retail pharmacies and online pharmacies across seven major regions.
Prurigo nodularis treatment Market by CategoryDrug Class
- CorticosteroidsInjectable
- Topical
- Oral
- Emollients
- Capsaicin Cream
- Antihistamines
- Anticonvulsants
- Antidepressants
- Neurokinin 1 Receptor (NK1R)
- Opiate Receptor Antagonists
- Others
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online sales
Region
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/3339
About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact:
Future Market Insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For Sales Enquiries: [email protected]
For Media Enquiries: [email protected]
Website: https://www.futuremarketinsights.com/
